Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapies.

Unkel S, Amiri M, Benda N, Beyersmann J, Knoerzer D, Kupas K, Langer F, Leverkus F, Loos A, Ose C, Proctor T, Schmoor C, Schwenke C, Skipka G, Unnebrink K, Voss F, Friede T.

Pharm Stat. 2019 Mar;18(2):166-183. doi: 10.1002/pst.1915. Epub 2018 Nov 20.

2.

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.

Aguirre AJ, Nowak JA, Camarda ND, Moffitt RA, Ghazani AA, Hazar-Rethinam M, Raghavan S, Kim J, Brais LK, Ragon D, Welch MW, Reilly E, McCabe D, Marini L, Anderka K, Helvie K, Oliver N, Babic A, Da Silva A, Nadres B, Van Seventer EE, Shahzade HA, St Pierre JP, Burke KP, Clancy T, Cleary JM, Doyle LA, Jajoo K, McCleary NJ, Meyerhardt JA, Murphy JE, Ng K, Patel AK, Perez K, Rosenthal MH, Rubinson DA, Ryou M, Shapiro GI, Sicinska E, Silverman SG, Nagy RJ, Lanman RB, Knoerzer D, Welsch DJ, Yurgelun MB, Fuchs CS, Garraway LA, Getz G, Hornick JL, Johnson BE, Kulke MH, Mayer RJ, Miller JW, Shyn PB, Tuveson DA, Wagle N, Yeh JJ, Hahn WC, Corcoran RB, Carter SL, Wolpin BM.

Cancer Discov. 2018 Sep;8(9):1096-1111. doi: 10.1158/2159-8290.CD-18-0275. Epub 2018 Jun 14.

3.

Analysis of endpoints used in marketing authorisations versus value assessments of oncology medicines in Germany.

Ruof J, Knoerzer D, Dünne AA, Dintsios CM, Staab T, Schwartz FW.

Health Policy. 2014 Nov;118(2):242-54. doi: 10.1016/j.healthpol.2014.08.004. Epub 2014 Aug 24.

4.

Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial.

Rahe-Meyer N, Solomon C, Hanke A, Schmidt DS, Knoerzer D, Hochleitner G, Sørensen B, Hagl C, Pichlmaier M.

Anesthesiology. 2013 Jan;118(1):40-50. doi: 10.1097/ALN.0b013e3182715d4d. Erratum in: Anesthesiology. 2013 May;118(5):1244.

PMID:
23249928
5.

Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis.

Hermann R, Nassr N, Lahu G, Péterfai E, Knoerzer D, Herzog R, Zech K, de Mey C.

Clin Pharmacokinet. 2007;46(5):403-16.

PMID:
17465639
6.

Magnesium hydroxide/aluminium hydroxide-containing antacid does not affect the pharmacokinetics of the targeted phosphodiesterase 4 inhibitor roflumilast.

Nassr N, Lahu G, Hünnemeyer A, von Richter O, Knoerzer D, Reutter F, Zech K, Hermann R.

J Clin Pharmacol. 2007 May;47(5):660-6. Epub 2007 Mar 20. No abstract available.

PMID:
17374735
7.

Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor.

Bethke TD, Böhmer GM, Hermann R, Hauns B, Fux R, Mörike K, David M, Knoerzer D, Wurst W, Gleiter CH.

J Clin Pharmacol. 2007 Jan;47(1):26-36.

PMID:
17192499
9.

Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects.

Nassr N, Lahu G, von Richter O, Reutter F, Knoerzer D, Zech K, Erb KA, Schug B, Blume H, Hermann R.

Br J Clin Pharmacol. 2007 Mar;63(3):365-70. Epub 2006 Sep 29.

10.

Drug intervention can correct subnormal retinal oxygenation response in experimental diabetic retinopathy.

Berkowitz BA, Roberts R, Luan H, Peysakhov J, Knoerzer DL, Connor JR, Hohman TC.

Invest Ophthalmol Vis Sci. 2005 Aug;46(8):2954-60.

PMID:
16043871
11.

Esomeprazole MUPS 40 mg tablets and esomeprazole MUPS 40 mg tablets encapsulated in hard gelatine are bioequivalent.

Talpes S, Knoerzer D, Huber R, Pfaffenberger B.

Int J Clin Pharmacol Ther. 2005 Jan;43(1):51-6.

PMID:
15704615
12.

Regulation of the early subnormal retinal oxygenation response in experimental diabetes by inducible nitric oxide synthase.

Berkowitz BA, Luan H, Gupta RR, Pacheco D, Seidner A, Roberts R, Liggett J, Knoerzer DL, Connor JR, Du Y, Kern TS, Ito Y.

Diabetes. 2004 Jan;53(1):173-8.

13.

Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides.

Agrawal S, Kandimalla ER, Yu D, Hollister BA, Chen SF, Dexter DL, Alford TL, Hill B, Bailey KS, Bono CP, Knoerzer DL, Morton PA.

Int J Oncol. 2001 May;18(5):1061-9.

PMID:
11295057
14.

Clinical and histological assessment of collagen-induced arthritis progression in the diabetes-resistant BB/Wor rat.

Knoerzer DB, Donovan MG, Schwartz BD, Mengle-Gaw LJ.

Toxicol Pathol. 1997 Jan-Feb;25(1):13-9.

PMID:
9061845
15.

Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig.

Knoerzer DB, Karr RW, Schwartz BD, Mengle-Gaw LJ.

J Clin Invest. 1995 Aug;96(2):987-93.

Supplemental Content

Loading ...
Support Center